Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology
company developing novel products for life science markets,
announced today its financial results for the first quarter ending
March 31, 2018.
Ofer Haviv, Evogene's President and CEO,
stated: “Evogene’s structure is built on three
Ag-divisions and two subsidiaries, with the Computational
Predictive Biology - CPB platform at its core. I am very pleased to
report that our first quarter of 2018 was highlighted with key
achievements in each of our areas of activity.
“In our Ag-Chemicals division, I am happy to
highlight the achievement of a new collaboration with BASF focusing
on the development of novel insecticides. I am very proud of this
achievement, not just because it is a second collaboration with
BASF in addition to our existing collaboration in the segment of
herbicides, but because we also announced achieving the first
milestone of identifying new sites-of-action for known protein
targets which is another demonstration of the quality of our
technology and capabilities.
“In our Ag-Seeds division, we recently announced
together with Marrone Bio-Innovations advancement to Phase I in our
joint collaboration. In this announcement, we shared the progress
of the first toxin genes against Hemipteran insects to Phase I,
leading our internal insect control seed trait product program to
include toxin genes in Phase I in all major insect orders:
Coleoptera, Lepidoptera and Hemiptera.
“In our Ag-Biologicals division, I am pleased
with the progress of the joint work in our collaboration with
Corteva (The Ag company established after the DowDuPont merger) for
the development of novel corn bio-stimulants. In our wheat program,
we will begin the harvest of our 2nd year field trial in the
upcoming weeks. In the segment of bio-pesticides, based on
promising greenhouse results in our bio-fungicides for fusarium in
corn and bio-insecticides for western corn rootworm, we are moving
forward with development efforts to further assess performance
across additional pests and environmental conditions.
“As for our subsidiaries, in Biomica, which is
focused on developing microbiome based therapeutics, I am very
pleased with the progress of this recently established subsidiary,
as can be seen in our recent press release, in which we announced
that Biomica’s focus will be on the development of therapeutics for
antibiotic resistant bacteria, Immuno-Oncology and GI related
disorders. Regarding our second subsidiary Evofuel, focusing on the
commercialization of castor seeds, we continue to see progress as
planned mainly in solving the bottleneck of mechanical
harvesting.
“Last but not least, I would like to emphasize,
as mentioned, that the CPB platform is at the core of our
activities. All the achievements described above have been made
possible thanks to the competitive advantage of the CPB platform
that allows us to decode the biological world, greatly accelerating
product development in a variety of life-science fields. We look
forward to sharing with you the progress in our diverse product
programs and expect 2018 to be a further demonstration of the CPB
platform's capabilities.” - Concluded Mr.
Haviv.
Financial results for the period ending
March 31, 2018
Cash Position: As of
March 31, 2018, the Company had $66.0 million in cash, short-term
bank deposits and marketable securities, representing a net cash
usage of $5.8 million for the first quarter of 2018. The cash usage
during the first quarter of 2018 includes pre-paid expenses and
non-recurring payments of approximately of $1.6 million. In
addition, we expect that in the following quarters the ongoing cash
usage will decrease. The Company does not have bank debts.
Assuming the currently expected course of
business and no new revenue sources from existing or new
collaborations, in 2018 Evogene expects net cash usage of $14 to
$16 million.
Revenues primarily consist
of research and development payments, reflecting R&D cost
reimbursement under our various collaboration agreements. The
majority of these agreements also provide for development milestone
payments and royalties or other forms of revenue sharing from
successfully developed products.
Revenues for the first quarter of 2018 were $0.4
million, in comparison to revenues of $0.7 million for the first
quarter in 2017. The decline in revenues and the related decline in
cost of revenues reflects the net decrease in research and
development cost reimbursement, under Evogene's various
collaboration agreements, mainly due to the advancement of our
multi-year collaboration with Monsanto from gene discovery and
validation in model plants, which was largely preformed at Evogene,
to pre-development efforts in target plants, conducted by
Monsanto.
R&D expenses for the first
quarter of 2018 were approximately $3.5 million in comparison to
approximately $4.0 million in the first quarter of 2017. During the
first quarter of 2018, we continued to support our existing
internal product programs and expanded new activities such as
Biomica. Despite these activities, R&D expenses decreased
following the new corporate structure initiated at the beginning of
2018.
Operating loss for the first
quarter of 2018 was $4.9 million in comparison to $5.3 million in
the first quarter in 2017. The decrease in operating loss was
mainly due to the decrease in R&D expenses as described above,
which was partially offset by a net increase in other expense
categories.
The net financing expenses for the first quarter
of 2018 were $0.4 million in comparison to a net financing income
of $0.4 million in the comparable quarter in 2017. This decrease is
mainly due to unrealized revaluation of marketable securities
following the increase in the US treasury bonds interest rate in
the first quarter of 2018.
Loss for the first quarter of
2018 was $5.4 million compared to a loss of $4.8 million in the
comparable quarter in 2017. Despite a decrease in operating loss
following the new corporate structure, as described above, the
increase in loss was due to an increase in the net financing
expenses.
Conference Call & Webcast
Details:
Evogene’s management will host a conference call
to discuss the results at 09:00 AM Eastern time, 16:00 Israel time.
To access the conference call, please dial 1-888-407-2553 toll free
from the United States, or +972-3-918-0610 internationally. Access
to the call will also be available via live webcast through the
Company’s website at www.evogene.com.
A replay of the conference call will be
available approximately three hours following the completion of the
call. To access the replay, please dial 1-888-782-4291 toll free
from the United States, or +972-3-925-5928 internationally. The
replay will be accessible through May 29, 2018, and an archive of
the webcast will be available on the Company’s website through June
8, 2018.
About Evogene
Ltd.:Evogene (NASDAQ:EVGN) (TASE:EVGN) is a leading
biotechnology company developing novel products for major life
science markets through the use of a unique predictive biology
platform incorporating deep scientific understandings and advanced
computational technologies. This platform is utilized by the
Company to discover and develop innovative ag-chemical,
ag-biological and ag-seed products (GM and non GM), and by two
subsidiaries; Evofuel, focused on castor seeds, and Biomica,
focused on human microbiome therapeutics. Through its
collaborations over the years with world-leading agricultural
companies such as BASF, DuPont, Bayer, Syngenta and Monsanto,
Evogene has licensed genes, small molecules and microbes to
partners under milestone and royalty bearing agreements. For more
information, please visit www.evogene.com
Forward Looking Statements:This
press release contains "forward-looking statements" relating to
future events. These statements may be identified by words such as
"may", "could", “expects”, "intends", “anticipates”, “plans”,
“believes”, “scheduled”, “estimates” or words of similar meaning.
Such statements are based on current expectations, estimates,
projections and assumptions, describe opinions about future events,
involve certain risks and uncertainties which are difficult to
predict and are not guarantees of future performance. Therefore,
actual future results, performance or achievements of Evogene may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which beyond Evogene's control, including, without limitation,
those risk factors contained in Evogene’s reports filed with the
appropriate securities authority. Evogene disclaims any obligation
or commitment to update these forward-looking statements to reflect
future events or developments or changes in expectations,
estimates, projections and assumptions.
Contact:Nir Zalik IR/PR
ManagerE: IR@evogene.comT: (+972)-8-931-1963
US Investor RelationsVivian Cervantes PCG
AdvisoryE: vivian@pcgadvisory.comT: 646-863-6274
|
CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION |
U.S. dollars in thousands
(except share and per share data) |
|
|
|
As of March 31, |
|
As of
December 31, |
|
|
|
2018 |
|
|
2017 |
|
|
2017 |
|
|
Unaudited |
|
Audited |
CURRENT
ASSETS: |
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
5,353 |
|
$ |
3,290 |
|
$ |
3,435 |
Marketable securities |
|
|
54,090 |
|
|
68,014 |
|
|
59,940 |
Short-term bank deposits |
|
|
6,500 |
|
|
12,017 |
|
|
8,380 |
Trade
receivables |
|
|
189 |
|
|
625 |
|
|
132 |
Other
receivables and prepaid expenses |
|
|
1,523 |
|
|
1,933 |
|
|
904 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,655 |
|
|
85,879 |
|
|
72,791 |
LONG-TERM ASSETS: |
|
|
|
|
|
|
Long-term
deposits |
|
|
19 |
|
|
4 |
|
|
19 |
Property,
plant and equipment, net |
|
|
4,375 |
|
|
6,017 |
|
|
4,792 |
|
|
|
|
|
|
|
|
|
|
4,394 |
|
|
6,021 |
|
|
4,811 |
|
|
|
|
|
|
|
|
|
$ |
72,049 |
|
$ |
91,900 |
|
$ |
77,602 |
CURRENT
LIABILITIES: |
|
|
|
|
|
|
Trade
payables |
|
$ |
911 |
|
$ |
778 |
|
$ |
1,110 |
Other
payables |
|
|
2,342 |
|
|
3,161 |
|
|
2,934 |
Liabilities in respect of government grants |
|
|
712 |
|
|
696 |
|
|
104 |
Deferred
revenues and other advances |
|
|
687 |
|
|
1,033 |
|
|
516 |
|
|
|
|
|
|
|
|
|
|
4,652 |
|
|
5,668 |
|
|
4,664 |
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
Liabilities in respect of government grants |
|
|
2,930 |
|
|
2,766 |
|
|
3,438 |
Deferred
revenues and other advances |
|
|
88 |
|
|
128 |
|
|
89 |
Severance
pay liability, net |
|
|
32 |
|
|
32 |
|
|
33 |
|
|
|
|
|
|
|
|
|
|
3,050 |
|
|
2,926 |
|
|
3,560 |
SHAREHOLDERS' EQUITY: |
|
|
|
|
|
|
Ordinary
shares of NIS 0.02 par value:Authorized − 150,000,000 ordinary
shares; Issued and outstanding –25,754,297, 25,626,809 and
25,750,547 shares at March 31, 2018 and 2017 and December 31,
2017, respectively |
|
|
142 |
|
|
141 |
|
|
142 |
Share
premium and other capital reserve |
|
|
186,623 |
|
|
184,206 |
|
|
186,268 |
Accumulated deficit |
|
|
(122,418) |
|
|
(101,041) |
|
|
(117,032) |
|
|
|
|
|
|
|
|
|
|
64,347 |
|
|
83,306 |
|
|
69,378 |
|
|
|
|
|
|
|
|
|
$ |
72,049 |
|
$ |
91,900 |
|
$ |
77,602 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF PROFIT OR
LOSS |
U.S. dollars in thousands (except share and per share
data) |
|
|
|
|
|
|
|
Three Months EndedMarch,
31 |
|
Year endedDecember
31, |
|
|
|
2018 |
|
|
2017 |
|
2017 |
|
|
Unaudited |
|
Audited |
|
|
|
|
|
|
|
Revenues |
|
$ |
366 |
|
$ |
721 |
|
$ |
3,381 |
Cost of revenues |
|
|
284 |
|
|
647 |
|
|
2,845 |
|
|
|
|
|
|
|
Gross profit |
|
|
82 |
|
|
74 |
|
|
536 |
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development, net |
|
|
3,485 |
|
|
4,004 |
|
|
16,987 |
Business development |
|
|
598 |
|
|
451 |
|
|
1,686 |
General and administrative |
|
|
945 |
|
|
878 |
|
|
3,810 |
|
|
|
|
|
|
|
Total operating expenses |
|
|
5,028 |
|
|
5,333 |
|
|
22,483 |
|
|
|
|
|
|
|
Operating loss |
|
|
(4,946) |
|
|
(5,259) |
|
|
(21,947) |
|
|
|
|
|
|
|
Financing income |
|
|
533 |
|
|
722 |
|
|
2,125 |
Financing expenses |
|
|
(970) |
|
|
(302) |
|
|
(1,005) |
|
|
|
|
|
|
|
Loss before taxes on income |
|
|
(5,383) |
|
|
(4,839) |
|
|
(20,827) |
Taxes on income |
|
|
3 |
|
|
8 |
|
|
11 |
|
|
|
|
|
|
|
Loss |
|
$ |
(5,386) |
|
$ |
(4,847) |
|
$ |
(20,838) |
|
|
|
|
|
|
|
Basic and diluted loss per share |
|
$ |
(0.21) |
|
$ |
(0.19) |
|
$ |
(0.81) |
|
|
|
|
|
|
|
Weighted average number of shares used in computing basic and
diluted loss per share |
|
|
25,750,673 |
|
|
25,500,471 |
|
|
25,673,276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF CASH
FLOWS |
U.S. dollars in thousands |
|
|
|
|
|
|
|
Three Months endedMarch,
31 |
|
Year endedDecember
31, |
|
|
2018 |
|
2017 |
|
2017 |
|
|
Unaudited |
|
Audited |
|
|
|
|
|
|
|
|
|
Cash
flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss |
|
$ |
(5,386) |
|
$ |
(4,847) |
|
$ |
(20,838) |
|
|
|
|
|
|
|
|
|
Adjustments to reconcile loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to the profit or loss items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
496 |
|
|
545 |
|
|
2,145 |
|
Share-based compensation |
|
|
346 |
|
|
516 |
|
|
2,244 |
|
Net
financing expense (income) |
|
|
411 |
|
|
(565) |
|
|
(1,454) |
|
Taxes on
income |
|
|
3 |
|
|
8 |
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
1,256 |
|
|
504 |
|
|
2,946 |
|
Changes
in asset and liability items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease
(increase) in trade receivables |
|
|
(57) |
|
|
(456) |
|
|
37 |
|
Decrease
(increase) in other receivables |
|
|
(622) |
|
|
(720) |
|
|
221 |
|
Decrease
(increase) in long-term deposits |
|
|
- |
|
|
9 |
|
|
(6) |
|
Decrease
in trade payables |
|
|
(230) |
|
|
(429) |
|
|
(86) |
|
Increase
(decrease) in other payables |
|
|
(588) |
|
|
357 |
|
|
136 |
|
Increase
(decrease) in severance pay liability, net |
|
|
(1) |
|
|
1 |
|
|
2 |
|
Increase
(decrease) in deferred revenues and other advances |
|
|
170 |
|
|
56 |
|
|
(500) |
|
|
|
|
|
|
|
|
|
|
|
|
(1,328) |
|
|
(1,182) |
|
|
(196) |
|
|
|
|
|
|
|
|
|
Cash
received (paid) during the period for: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
received |
|
|
533 |
|
|
671 |
|
|
2,173 |
|
Taxes
paid |
|
|
(7) |
|
|
(11) |
|
|
(14) |
|
|
|
|
|
|
|
|
|
Net cash
used in operating activities |
|
|
(4,932) |
|
|
(4,865) |
|
|
(15,929) |
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
of property, plant and equipment |
|
|
(48) |
|
|
(198) |
|
|
(590) |
|
Proceeds
from sale of marketable securities |
|
|
7,222 |
|
|
6,286 |
|
|
22,737 |
|
Purchase
of marketable securities |
|
|
(2,204) |
|
|
(2,704) |
|
|
(11,659) |
|
Proceeds
from bank deposits, net |
|
|
1,880 |
|
|
1,120 |
|
|
4,757 |
|
|
|
|
|
|
|
|
|
Net cash
provided by investing activities |
|
|
6,850 |
|
|
4,504 |
|
|
15,245 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF CASH
FLOWS |
U.S. dollars in thousands |
|
|
|
|
|
|
|
Three Months endedMarch,
31 |
|
Year endedDecember
31, |
|
|
|
2018 |
|
2017 |
|
2017 |
|
|
Unaudited |
|
Audited |
|
|
|
|
|
|
|
Cash
flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds
from exercise of options |
|
|
9 |
|
|
348 |
|
|
683 |
Proceeds
from government grants |
|
|
57 |
|
|
101 |
|
|
339 |
Repayment of government grants |
|
|
(44) |
|
|
(94) |
|
|
(208) |
|
|
|
|
|
|
|
Net cash
provided by financing activities |
|
|
22 |
|
|
355 |
|
|
814 |
|
|
|
|
|
|
|
Exchange
rate differences - cash and cash equivalent balances |
|
|
(22) |
|
|
60 |
|
|
69 |
|
|
|
|
|
|
|
Increase
in cash and cash equivalents |
|
|
1,918 |
|
|
54 |
|
|
199 |
|
|
|
|
|
|
|
Cash and
cash equivalents, beginning of the period |
|
|
3,435 |
|
|
3,236 |
|
|
3,236 |
|
|
|
|
|
|
|
Cash and
cash equivalents, end of the period |
|
$ |
5,353 |
|
$ |
3,290 |
|
$ |
3,435 |
|
|
|
|
|
|
|
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Apr 2023 to Apr 2024